Skip to content

Choroidal Changes Post Short Term Exposure To Virtual Reality Devices

Choroidal Changes Post Short Term Exposure To Virtual Reality Devices

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04140877
Acronym
MIRABILE
Enrollment
0
Registered
2019-10-28
Start date
2020-07-31
Completion date
2021-01-31
Last updated
2020-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Keywords

Choroidal thickness, Virtual reality

Brief summary

This is a prospective, randomized, controlled, contralateral eye, clinical study. The objective of the study is to determine the impact of Virtual Reality (VR) usage on choroidal thickness when viewed through a test display compared to a control (standard) VR display. The hypothesis is that there will be less choroidal thinning in the eye viewing the test VR screen compared to the eye viewing the control VR screen.

Interventions

DEVICEVisu

An experimental (test) virtual reality display

Sponsors

Visu, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

Randomized, contralateral eye study

Eligibility

Sex/Gender
ALL
Age
13 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Key Inclusion Criteria: * Is at least 13 years of age and has full legal capacity to volunteer; * Has read and signed an information consent letter; * Visual Acuity of +0.20 logMAR or better in each eye; * Is willing and able to follow instructions and maintain the appointment schedule. Key

Exclusion criteria

* Is participating in any concurrent clinical or research study; * Has any known active ocular disease and/or infection; * Has a systemic condition that in the opinion of the investigator may affect a study outcome variable; * Is amblyopic in either eye; * Has a colour vision abnormality; * Commonly experiences motion sickness.

Design outcomes

Primary

MeasureTime frame
Choroidal thickness2 hours

Secondary

MeasureTime frame
Choroidal thickness3 months
Axial length3 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026